Arrowhead Pharmaceuticals (ARWR) is down 7.5% today. Here is some analysis on what might have caused this price movement.
Analysis: The most likely explanation is profit-taking after a strong recent run, rather than a clearly negative new company-specific development. Arrowhead has had favorable momentum from recent regulatory progress for REDEMPLO and index-related visibility, so a sharp pullback can happen when traders lock in gains and the market lacks a fresh upside catalyst.
Details:
Arrowhead recently announced European Union marketing authorization for REDEMPLO for adults with familial chylomicronemia syndrome, extending the company’s commercial story beyond the U.S.Recent company materials pointed to an important second half of 2026 for its cardiometabolic pipeline, which likely helped fuel earlier optimism in the shares.A July 9 market note highlighted Arrowhead’s move into larger Russell indexes, a change that can affect fund flows, trading volumes, and short-term volatility.There does not appear to be a new July 10 company filing or press release that cleanly explains a 7.5% drop, so this could be because traders are unwinding positions after the recent rally.Sources:
Arrowhead Pharmaceuticals, SEC, Simply Wall St ([ir.arrowheadpharma.com](https://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-pharmaceuticals-receives-marketing-authorization?utm_source=openai))
Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.
$ARWR Insider Trading Activity
$ARWR insiders have traded $ARWR stock on the open market 6 times in the past 6 months. Of those trades, 0 have been purchases and 6 have been sales.
Here’s a breakdown of recent trading of $ARWR stock by insiders over the last 6 months:
- JAMES C HAMILTON (Chief Medical Officer) has made 0 purchases and 2 sales selling 20,000 shares for an estimated $1,391,900.
- DANIEL JOSEPH APEL (Chief Financial Officer) has made 0 purchases and 3 sales selling 13,095 shares for an estimated $934,285.
- HONGBO LU sold 2,970 shares for an estimated $228,333
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
Quiver Alerts
Receive ARWR Data Alerts
Get market-moving data, filings, and signals for ARWR in real time.
Sign Up
$ARWR Hedge Fund Activity
We have seen 235 institutional investors add shares of $ARWR stock to their portfolio, and 152 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BLACKROCK, INC. removed 3,157,063 shares (-14.8%) from their portfolio in Q1 2026, for an estimated $197,947,850
- SLATE PATH CAPITAL LP removed 2,523,500 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $158,223,450
- FRED ALGER MANAGEMENT, LLC added 1,509,496 shares (+82.4%) to their portfolio in Q1 2026, for an estimated $94,645,399
- ARROWSTREET CAPITAL, LIMITED PARTNERSHIP removed 1,500,828 shares (-71.9%) from their portfolio in Q1 2026, for an estimated $94,101,915
- VESTAL POINT CAPITAL, LP added 1,375,000 shares (+152.8%) to their portfolio in Q1 2026, for an estimated $86,212,500
- HOOD RIVER CAPITAL MANAGEMENT LLC added 1,056,534 shares (+inf%) to their portfolio in Q1 2026, for an estimated $66,244,681
- RENAISSANCE TECHNOLOGIES LLC added 1,036,495 shares (+inf%) to their portfolio in Q1 2026, for an estimated $64,988,236
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$ARWR Price Targets
Multiple analysts have issued price targets for $ARWR recently. We have seen 9 analysts offer price targets for $ARWR in the last 6 months, with a median target of $90.0.
Here are some recent targets:
- Patrick R. Trucchio from HC Wainwright & Co. set a target price of $100.0 on 07/01/2026
- Keay Nakae from Chardan Capital set a target price of $90.0 on 06/30/2026
- Mani Foroohar from Leerink Partners set a target price of $72.0 on 06/17/2026
- William Pickering from Bernstein set a target price of $46.0 on 05/13/2026
- Luca Issi from RBC Capital set a target price of $87.0 on 05/08/2026
- Brian Cheng from JP Morgan set a target price of $88.0 on 05/01/2026
- Michael Ulz from Morgan Stanley set a target price of $100.0 on 04/21/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Read full article here »
View the Zacks #1 Rank List
Arrowhead Pharmaceuticals Slides as Investors Appear to Take Profits After Recent Catalyst-Driven Run
Arrowhead Pharmaceuticals (ARWR) is down 7.5% today. Here is some analysis on what might have caused this price movement.
Analysis: The most likely explanation is profit-taking after a strong recent run, rather than a clearly negative new company-specific development. Arrowhead has had favorable momentum from recent regulatory progress for REDEMPLO and index-related visibility, so a sharp pullback can happen when traders lock in gains and the market lacks a fresh upside catalyst.
Details:
Sources:
Arrowhead Pharmaceuticals, SEC, Simply Wall St ([ir.arrowheadpharma.com](https://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-pharmaceuticals-receives-marketing-authorization?utm_source=openai))
Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.
$ARWR Insider Trading Activity
$ARWR insiders have traded $ARWR stock on the open market 6 times in the past 6 months. Of those trades, 0 have been purchases and 6 have been sales.
Here’s a breakdown of recent trading of $ARWR stock by insiders over the last 6 months:
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$ARWR Hedge Fund Activity
We have seen 235 institutional investors add shares of $ARWR stock to their portfolio, and 152 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$ARWR Price Targets
Multiple analysts have issued price targets for $ARWR recently. We have seen 9 analysts offer price targets for $ARWR in the last 6 months, with a median target of $90.0.
Here are some recent targets:
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Read full article here »